Director's Desk

In 1962, about 54 years ago, "Cholera Research Centre" was established in Calcutta (Kolkata) by Indian Council of Medical Research (ICMR) to conduct research on prevention and control of cholera and other diarrheal diseases.In 1968, the Centre was given the status of "International Reference Centre for Vibrio Phage Typing" by the WHO following the outstanding studies on cholera phages in Kolkata and later on, in 1978, it was designated as the "WHO Collaborative Centre for Reference and Research on Vibrios". Subsequently, ICMR converted this Centre into a full-fledged research organization with the status of a "National Institute" and renamed it as "National Institute of Cholera and Enteric Diseases" (NICED) in 1979. The WHO recognized this Institute as "WHO Collaborative Centre for Research and Training on Diarrhoeal Diseases" in 1980. More

Dr Rajiv Bahl

Secretary to Government of India, Department of Health Research
Director General, Indian Council of Medical Research

Dr Rajiv Bahl is a physician-scientist, with specialization in paediatrics (MD Pediatrics: University of Delhi) and public health (PhD: All India Institute of Medical Sciences). He received an Honorary Doctorate from University of Bergen, Norway, in 2022 in recognition of his contributions to maternal and child health research.

Dr Bahl has demonstrated leadership in health research and translating research to public health policy both in India and at a global level over the past three decades. His prolific scholarly output includes over 250 papers in peer reviewed journals and an H-Index of 78 that positions him among top 1.25% scientists in the world across all disciplines. View Profile

News & Events

• 
  DengiAll-Phase-III-Vaccine Trial at ICMR-NIRBI: Call for participation

  ICMR- National Institute for Research in Bacterial Infections (ICMR-NIRBI), a premier research organization, under the Dept. of Health Research, Ministry of Health and Family Welfare, Govt. of India, is going to initiate a Drug Controller General of India (DCGI) approved trial titled "A Phase III, Multicenter, Randomized, Double- Blind, Placebo-Controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of Single dose of Dengue Tetravalent Vaccine, Live Attenuated (Recombinant, Lyophilized) - 'DengiAll' of Panacea Biotic Limited in Healthy Indian Adults". The objectives of the study are to evaluate the efficacy against Dengue fever and to determine the safety and Immunogenicity of the dengue vaccine - 'DengiAll' in healthy adults. Participants of any gender of aged between 18-60 years, residing in Kolkata (preferably within 10 kms. of ICMR-NIRBI) are encouraged to participate voluntarily in this trial. Willing participants are requested to contact in this number (9903824322) or email ( DengiAllnirbi@gmail.com ) their personal details (name, age, sex, address, contact number, email, and comorbidities, if any) for further information. A limited number of participants will be enrolled in the study and they will be screened for eligibility criteria before enrolment in the study. The participant enrolment will continue till the target is achieved.. View Details

• 

  Five-Day Workshop on Capacity Building in Systematic Review & Meta-Analysis
  Organized by : ICMR - National Institute for Cholera and Enteric Diseases
  in collaboration with World Health Organization
  05 to 09 August 2024 | 10:00 A.M. - 05:30 P.M.
  View Workshop Brochure

• Renaming of ICMR Institutes in pursuance of interim recommendations made by the Performance Evaluation Committee.
  No. 16//18/2024-Admn./e- 184719  Dated: 28/05/2024
  In continuation to ICMR Office Memorandum of even number dated 10/04/2024 on
  the subject mentioned above, the ICMR- NICED was transformed and renamed as "National Institute of Bacterial Infections". Now, DG ICMR has decided to incorporate the term "research" and Institute is now renamed as "ICMR-National Institute for Research in Bacterial Infections" (ICMR-NIRBI).
  Henceforth, all future correspondence may be addressed at the new name of the Institute.
  View Notice [PDF]

• 

  ACSIR Ph.D. Programme
  View Details [PDF]

• 

  
  Topic: Foundation Day 2024
  Time: Mar 1, 2024 11:00 AM Mumbai, Kolkata, New Delhi
  View Invitation [PDF]

  Joining Details

  Join Zoom from PC, Mac, iOS or Android: 

  https://echo.zoom.us/j/84208011176

  Meeting ID: 842 0801 1176

• 

  Swachhata Hi Seva
  15 September - 2 October 2023
  Garbage Free India

Impact assessment of administering Oral Cholera Vaccine in selected cholera vulnerable districts of West Bengal.

- An Vaccine implementation Research by ICMR- NICED in collaboration with State Public Health System, Govt of West Bengal.

Cholera remains a global public health problem with developing countries bearing the burnt many folds. WHO - Global Task Force on Cholera Control (GTFCC) has declared to End Cholera by 2030 to which India is also committed as a Nation.

Prevention of Cholera outbreak always remained a challenge in countries like India where there are lots of slum populations with high population density. Achieving cholera control through improving water, hygiene, and sanitation may not be feasible at times and require sustained effort and commitment. In such a situation, the Oral Cholera Vaccine (OCV) is an important intervention to address immediately the cholera outbreak menace.

In this regard, ICMR-NICED Kolkata is taking the initiative through an ICMR-funded project for health system implementation of OCV in selected cholera-vulnerable districts of West Bengal utilizing the state health machinery so that effectiveness, challenges, and future policy decisions on requirements of programmatic introduction of OCV may be monitored from real health system perspective.

Euvichol-Plus is an OCV containing inactivated whole cell (WC) of Vibrio cholerae O1 and O139 as active ingredients. It is very safe and around 65% efficacious as evidenced from earlier Randomized Control Trials. The study vaccine (Euvichol-Plus) has been registered in multiple countries, with WHO prequalification for use in subjects 1 year and above. Euvichol-Plus has been procured from UN agencies at subsidized rate, comprising more than 90% of OCV supply to cholera-endemic countries worldwide.

The primary objective is to evaluate the impact of OCV implementation in cholera-endemic zones of West Bengal in a real time situation through a mass vaccination campaign using the public healthcare delivery system. Other specific research components will also be included, like :

• Age group of target population: children of 1 year and above from cholera-endemic areas, excluding pregnant/lactating women and seriously ill individuals.
• Oral cholera vaccine (OCV), Euvichol-Plus, will be administered through urban municipality primary health centres or other booths at selected Urban wards (areas with dense clusters in city study map above) with a dosing schedule of Day 0 and Day 14, targeting a total population of around 50,000.
• The vaccine, WHO-prequalified in 2017, has demonstrated sufficient safety and immunogenicity.
• Post-vaccination, diarrhoeal disease surveillance network will be in place to monitor and document diarrheal episodes through.

COVID-19 Status Update ICMR-NIRBI

View all updates

Information Regarding Testing of Samples for SARS-CoV-2 in the Emergency Situation
View COVID-19 Guidelines: Information Regarding Testing of Samples for SARS-CoV-2 in the Emergency Situation

Guideline for sending suspected monkey pox samples

View Guideline for sending Monkeypox suspected samples to NICED

ANNEXURE I | ANNEXURE II | ANNEXURE III

About NIRBI

NIRBI moved from the rented premises at No. 3 Kyd Street to its own establishment at P-33, C.I.T. Road, Scheme XM, Beliaghata, Kolkata 700010, adjacent to the Infectious Diseases Hospital. The unique feature of this Institute is that it conducts basic research and applied clinical and epidemiological research on diarrhoeal diseases under the same roof. This Institute has its basic science set up with well equipped, modern technological facilities in different disciplines such as bacteriology, virology, parasitology, biochemistry, pathophysiology, molecular biology, electron microscopy, immunology and biochemistry.  Read more...

Notifications

Our Services